Replimune Group, Inc. · NASDAQ:REPL

Replimune — JPM Healthcare Conference 2026

30 slides from Replimune's conference presentation, Jan 14, 2026

Slide 1: Igniting a systemic immune response to cancer with oncolytic immunotherapy
January 14, 2026 Click to edit Master title style JPM Healthcare Conference Igniting a systemic immune response to cancer with oncolytic immunotherapy © 2026 Replimune Group Inc. 1 Click to edit Master text styles JPM 2026 Presentation
Slide 2: Safe harbor
Safe harbor Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements
Slide 3: Poised to Deliver on the Promise of Oncolytic Immunotherapy
Poised to Deliver on the Promise of Oncolytic Immunotherapy Sushil Patel, PhD CEO, Replimune © 2026 2025 Replimune Group Inc. 3
Slide 4: Oncolytic Immunotherapy: Overcoming Historical Hurdles
ClickOncolytic RPx to edit Master Immunotherapy title style Overcoming Historical Hurdles ~1,000 Patients ~150 Accounts ~1,200 Deep Injections Treated Across the Ready on Day 1 Administered RPx Platform Near-term PDUFA date of April 10, 2026 for melanoma Ability to inject RPx into deep Durable and s
Slide 5: RPx Platform Intended to Activate Systemic Immune Response
ClickPlatform RPx to edit Master Intended titleto style Activate Systemic Immune Response Injection Based on Superficial Only Deep/Visceral +/- RPx Immune Activating Pay Loads Lesion Location Injection Injection GALV-GP R- GM-CSF Anti-CTLA-4 Superficial Anti-PD-1 Therapy Deep/Visceral RPx engineerin
Slide 7: IGNYTE Study in Anti-PD-1 Failed Melanoma: Rigorous Criteria
IGNYTE Study Click to edit in Anti-PD-1 Master Failed Melanoma: title style Rigorous Criteria for Anti-PD-1 failure 28 days 28 days 22weeks weeks RP1+nivolumab 2 2 weeks weeks 2 weeks 2 weeks RP1 Nivolumab Nivolumab Screening 1×106 pfu/mL 1×107 pfu/mL, 240 mg 480 mg (Q4W) Anti-PD-1 failed 240 mg mel
Slide 8: Clinically Meaningful ORR in Resistant Subgroups
Click to edit Clinically Meaningful Master title ORRstyle in Resistant Subgroups Prior anti-PD-1 Stage Primary Secondary BOR All patients with IVb–IVd resistance resistance n (%) (N = 140) anti-CTLA-4 (n = 68) (n = 92)a (n = 48)b,c (n = 65) CR 23 (16.4) 6 (9.2) 4 (5.9) 16 (17.4) 7 (14.6) PR 24 (17.1
Slide 9: Responses with RP1 plus Nivolumab vs. Prior Anti-PD-1 Regimen
Responses with RP1 plus Nivolumab in the IGNYTE Study vs. Click to editPrior Immediate Master title style Anti-PD-1 Regimen Summary of Response on Immediate Prior Anti-PD-1 and in the IGNYTE Study (N=104) IGNYTE Time on Prior ORR on prior PD-1 ORR Non-Adjuvant Patient Treatment months based therapy
Slide 10: Time to Progression with RP1 plus Nivolumab vs. Prior Anti-PD-1 Regimen
Time to Progression with RP1 plus Nivolumab vs. Click to editPrior Immediate Master title style Anti-PD-1 Regimen Pre versus post Therapy Time to Progression Pre versus post Therapy Time to Progression (all IGNYTE patients) (responders only) 1 1 Median (95% CI) 0.9 Post Therapy: 3.58 [2.04, 4.96] 0.
Slide 11: Confirmatory IGNYTE-3 Study: Enrollment on Track
Click to edit Master Confirmatory IGNYTE-3 title style Study: Enrollment on Track Interim Analysis – OS Randomized 1:1 Advanced cutaneous melanoma RP1 + Nivolumab (n=200) >60 Progressed on anti-PD-1 AND patients anti-CTLA-4 OR enrolled not candidates for Treatment of Physician’s Choice (TPC*) anti-C
Slide 12: Prepared for Commercial Launch Success in Melanoma
Click to edit Master title style Prepared for Commercial Launch Success in Melanoma © 2026 Replimune Group Inc. 12 Click to edit Master text styles © 2025 Replimune Group Inc. 12 JPM 2026 Presentation
Slide 13: ~10K Addressable Patients Across Lines of Therapy
Click Addressable ~10K to edit MasterPatients title style Across Lines of Therapy US Melanoma Patient Treatment Funnel Early PD-1 Containing Stage Surgery Only Regimens ~2K PD-1 Containing BRAF/ 1L Adj refractory Regimens1 MEK 80% of patients who progress on PD-1 across lines of therapy are 2L ~7K N
Slide 14: Image Guidance Will Enable Broader Usage of RP1 through Interventional Radiology
Image Guidance Will Enable Broader Usage of RP1 through Click to edit Master Interventional title style Radiology Injection In-Office Injection via Image Guidance for Deep Lesions* ~20% of pts require only ~20% of pts have ~60% of pts only have deep lesions superficial injections superficial and dee
Slide 15: Interventional Radiologists Excited to Play a New Role in Immunotherapy Treatment
Interventional Radiologists Excited to Play a New Role in Click to edit Master Immunotherapy title style Treatment >520K US interventional oncology procedures performed in 20241; expected to increase Diagnostics Therapeutics Biopsies TARE/Y-90 Ablations TACE RPx Potential New Option “Seeing this lev
Slide 16: Initial U.S. Melanoma Launch Focus: 150 Accounts
Initial Click U.S. to Melanoma edit Master Launch title style Focus: 150 Accounts Expansion into 200 additional accounts within 6 to 9 months ~70 patients have received RP1 via Compassionate Use or Expanded Access © 2026 Replimune Group Inc. 16 Click to edit Master text styles JPM 2026 Presentation
Slide 17: U.S. Manufacturing Ready for Commercialization
ClickManufacturing U.S. to edit Master Ready title style for Commercialization State-of-the-art facility for end-to-end GMP manufacturing Fill-finish Drug substance production Commercial supply Packaging ready for market & labeling © 2026 Replimune Group Inc. 17 Click to edit Master text styles JPM
Slide 18: Opportunities in Skin Cancers Beyond Melanoma
Click to edit Master title style Opportunities in Skin Cancers Beyond Melanoma © 2026 Replimune Group Inc. 18 Click to edit Master text styles © 2025 Replimune Group Inc. 18 JPM 2026 Presentation
Slide 19: Expanding into Other Skin Cancers with a Novel Approach
Click to editinto Expanding Master Other title Skin style Cancers with a Novel Approach Monotherapy in Patients Unable to Receive Checkpoint Inhibitors Melanoma & Skin Cancers • Immunocompromised solid organ transplant (SOT) patients (ARTACUS study) • Patients' ineligible for Immunotherapy or • PD1-
Slide 20: Deep and Durable RP1 Monotherapy Responses in Locally Advanced CSCC in SOT Patients
Deep and Durable RP1 Monotherapy Responses in Locally Click to editCSCC Advanced Master intitle Solidstyle Organ Transplant (SOT) Patients Results from the ARTACUS Study Heart Transplant Patient Example Confirmed Best overall Intend To Treat Population (n=26) Baseline (C1) Week 30 (C16) response,
Slide 21: Complete Responses Observed in RP1 Monotherapy in Low Risk, Resectable cSCC
Complete Responses Observed in RP1 Monotherapy in Low Click to edit Master Risk, Resectable title style cSCC Neoadjuvant Pathological Confirmed BOR, Clinical Response Response n (%) (n=12) (n=12) ORR 12 (100) 12 (100) 8 (67) "It’s incredibly exciting, all but 2 lesions CR 10 (83)* No surgery needed
Slide 22: Expanding the RPx Opportunity via Deep Injections
Click to edit Master title style Expanding the RPx Opportunity via Deep Injections © 2026 Replimune Group Inc. 22 Click to edit Master text styles © 2025 Replimune Group Inc. 22 JPM 2026 Presentation
Slide 23: Broad Tumor Injectability with ~1,200 Deep RPx Injections Successfully Conducted
Broad Tumor Injectability with ~1,200 Deep RPx Injections Click to edit Master Successfully title style Conducted Metastases in the ORR benefit observed liver/lung is common & acceptable safety and difficult to treat* profile with RPx deep/ visceral injections RP2 HCC/BTC ~800 lung & liver Ph1 cohor
Slide 24: Enhanced ORR with Deep/Visceral Injections with Acceptable Safety
Enhanced ORR with Deep/Visceral (+ superficial) Injections with Click to editSafety Acceptable MasterDemonstrated title style in the IGNYTE study Safety by Injection Location (most common TRAEs) Superficial Deep/visceral ± only superficial Preferred (n = 104) (n = 36) term (%) Efficacy by Injection
Slide 25: Liver and Lung are the Most Common Sites of Metastasis for Cancer
Liver and Lung are the Most Common Sites of Metastasis Click to edit Master title style for Cancer Cancers Metastasizing to Liver Cancers Metastasizing to Lung • Uveal melanoma (70%+) • Osteosarcoma (75-85%) • Colorectal cancer (30-50%) • Prostate cancer (46%) • Neuroendocrine tumor (20-46%) • Renal
Slide 26: Metastatic Uveal Melanoma: ~70% of Patients Have Liver Metastases
Metastatic Uveal Melanoma: ~70% of Patients Have Liver Click to edit Master title style Metastases Phase 1 Study RP2 monotherapy RP2 + nivolumab Total Confirmed BOR, n (%) (n = 3) (n = 14) (N = 17) ORR (CR + PR) 1 (33.3) 4 (28.6) 5 (29.4) • Total of 47 liver lesion injections (12/17 pts) DCR (CR + P
Slide 27: Liver Mets/Liver-focused RP2 Studies are Well Underway
ClickLiver RP2 to edit Mets/Liver-focused Master title style Studies are Well Underway Registrational Phase 2/3 REVEAL Study Ongoing in Signal seeking study in: Metastatic Uveal Melanoma 2L PD-(L)1 Failed HCC 1:1 randomization with and PFS/OS endpoints Biliary Tract Cancer (BTC) Maintenance n=280 ~5
Slide 28: RPx Beyond Skin Cancers: Potential to Reach up to ~130K Patients in the U.S.
RPx Beyond Skin Cancers: Click to edit Potential MasterUp to Reach title tostyle ~130K Patients in the U.S. RP1 RP2 RPx • PD1-failed Melanoma • PD-1 failed NSCLC • PD-1 naïve Uveal (PDUFA pending) Basket melanoma • NMSC including PD-1 • PD-1 failed • PD-1 failed HCC failed (CSCC, MCC, BCC) Esophagog
Slide 29: Corporate Highlights
Click to edit Corporate Highlights Master title style 7 Ongoing Clinical Trials In-house U.S. based Near-term PDUFA Date with RP1 and RP2 to Manufacturing Facility for RP1 in Anti-PD-1 Support RPx with RP1 Launch Supply Failed Melanoma Expansion Produced Poised for Commercial Broad Market Launch Suc

Replimune Group — JPM Healthcare Conference 2026 on 6ix

Replimune — JPM Healthcare Conference 2026

Slide 1: Igniting a systemic immune response to cancer with oncolytic immunotherapy

Slide 2: Safe harbor

Slide 3: Poised to Deliver on the Promise of Oncolytic Immunotherapy

Slide 4: Oncolytic Immunotherapy: Overcoming Historical Hurdles

Slide 5: RPx Platform Intended to Activate Systemic Immune Response

Slide 6: Anti-PD-1 Failed Melanoma (IGNYTE)

Slide 7: IGNYTE Study in Anti-PD-1 Failed Melanoma: Rigorous Criteria

Slide 8: Clinically Meaningful ORR in Resistant Subgroups

Slide 9: Responses with RP1 plus Nivolumab vs. Prior Anti-PD-1 Regimen

Slide 10: Time to Progression with RP1 plus Nivolumab vs. Prior Anti-PD-1 Regimen

Slide 11: Confirmatory IGNYTE-3 Study: Enrollment on Track

Slide 12: Prepared for Commercial Launch Success in Melanoma

Slide 13: ~10K Addressable Patients Across Lines of Therapy

Slide 14: Image Guidance Will Enable Broader Usage of RP1 through Interventional Radiology

Slide 15: Interventional Radiologists Excited to Play a New Role in Immunotherapy Treatment

Slide 16: Initial U.S. Melanoma Launch Focus: 150 Accounts

Slide 17: U.S. Manufacturing Ready for Commercialization

Slide 18: Opportunities in Skin Cancers Beyond Melanoma

Slide 19: Expanding into Other Skin Cancers with a Novel Approach

Slide 20: Deep and Durable RP1 Monotherapy Responses in Locally Advanced CSCC in SOT Patients

Slide 21: Complete Responses Observed in RP1 Monotherapy in Low Risk, Resectable cSCC

Slide 22: Expanding the RPx Opportunity via Deep Injections

Slide 23: Broad Tumor Injectability with ~1,200 Deep RPx Injections Successfully Conducted

Slide 24: Enhanced ORR with Deep/Visceral Injections with Acceptable Safety

Slide 25: Liver and Lung are the Most Common Sites of Metastasis for Cancer

Slide 26: Metastatic Uveal Melanoma: ~70% of Patients Have Liver Metastases

Slide 27: Liver Mets/Liver-focused RP2 Studies are Well Underway

Slide 28: RPx Beyond Skin Cancers: Potential to Reach up to ~130K Patients in the U.S.

Slide 29: Corporate Highlights

Slide 30: Thank You